Floatz logo

Bel-Sar

Ocular Melanoma

Aura BiosciencesPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Ocular Melanoma cohort.

Asset / SponsorPhaseRating
BELZUPACAP SAROTALOCAN
Aura Biosciences
Phase 2BB
Ipilimumab
University of Michigan Rogel Cancer Center
Phase 2BB
Polyiclc
Craig L Slingluff, Jr
Phase 2B
Nivolumab
University of Michigan Rogel Cancer Center
Phase 2B
Aflibercept
Centre Hospitalier Universitaire de Nice
Phase 3B

View all 25 →

Same molecule, other indications

Bel-Sar is also rated in:

malignant choroid melanomaDormant
B
Indicative ·
60 / 100
View asset →
Indeterminate LesionsDormant
B
Indicative ·
60 / 100
View asset →
uveal melanomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →